Three drugs: Fosamax, Evista and Actonel dominate the osteoporosis treatment market, and a fourth drug, Boniva, recently became available.
Teva Pharmaceutical successfully fought Read the rest of this entry »
Three drugs: Fosamax, Evista and Actonel dominate the osteoporosis treatment market, and a fourth drug, Boniva, recently became available.
Teva Pharmaceutical successfully fought Read the rest of this entry »
Leave a Comment » |
Israel Related, News, Patents, Teva, US Patent Office, pharmaceuticals and Biotechnology |
Permalink
Posted by Dr Michael Factor
Teva has now received final approval to market a generic version of Pfizer’s Antidepressant, Zoloft®. The drug has 3 billion dollars of sales annually, and has been around for 14 years. Teva’s version will be available within weeks.
Zoloft® (sertraline HCl) is a selective serotonin Read the rest of this entry »
Leave a Comment » |
Israel Related, News, Patents, Teva, pharmaceuticals and Biotechnology |
Permalink
Posted by Dr Michael Factor
In a recent ruling, on 25 June 2006, Dr. Meir Noam, the Israel Commissioner of Patents has upheld a decision of the Trademark Department not to allow registration of the marks Lencor and Lengo for domestic appliances. Read the rest of this entry »
Leave a Comment » |
Israel IP, Israel Patent Office Rulings, Israel Related, Israel Trademark, News, Opinion, trademarks |
Permalink
Posted by Dr Michael Factor
You are currently browsing the The IP Factor blog archives for the day Sunday, July 2nd, 2006.

Dr. Michael Factor is an Israel Patent Attorney and partner of JMB, Factor & Co. Israel's International IP Firm.
Theme Contempt by Vault9.
Blog at WordPress.com.